Price$5.54-0.04 (-0.63%)
01:30 PM07:45 PM
News · 26 weeks72+17%
2025-12-142026-06-07
Mix3390d
- Insider13(39%)
- Other9(27%)
- SEC Filings7(21%)
- Leadership2(6%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by Ardelyx Inc.DEFA14A - ARDELYX, INC. (0001437402) (Filer)
- INSIDEROfficer Reilly Joseph James sold $23,309 worth of shares (3,719 units at $6.27), decreasing direct ownership by 1% to 149,836 units (SEC Form 4) (withholding tax)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Financial Officer Hohenleitner Susan sold $9,119 worth of shares (1,455 units at $6.27), decreasing direct ownership by 0.63% to 229,078 units (SEC Form 4) (for withholding tax)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDEROfficer Bishop John E sold $14,453 worth of shares (2,306 units at $6.27), decreasing direct ownership by 0.68% to 336,845 units (SEC Form 4) (tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Human Resources Officer Brady James Parker sold $11,570 worth of shares (1,846 units at $6.27), decreasing direct ownership by 0.70% to 261,066 units (SEC Form 4) to satisfy tax liability4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Commercial Officer Foster Eric Duane sold $50,127 worth of shares (7,998 units at $6.27), decreasing direct ownership by 2% to 417,972 units (SEC Form 4) to satisfy withholding obligation4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Business Officer Kelliher Mike sold $45,427 worth of shares (7,248 units at $6.27), decreasing direct ownership by 2% to 357,418 units (SEC Form 4) to cover withholding tax4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Patient Officer Williams Laura A sold $43,804 worth of shares (6,989 units at $6.27), decreasing direct ownership by 2% to 429,093 units (SEC Form 4) (withholding obligation)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERPresident & CEO Raab Michael sold $343,133 worth of shares (54,748 units at $6.27), decreasing direct ownership by 3% to 1,720,033 units (SEC Form 4) (withholding obligation)4 - ARDELYX, INC. (0001437402) (Issuer)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form DEFA14A filed by Ardelyx Inc.DEFA14A - ARDELYX, INC. (0001437402) (Filer)
- INSIDERPresident & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $261,612 worth of shares (41,666 units at $6.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,774,781 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- PRArdelyx to Participate at the Jefferies Global Healthcare Conference 2026WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York. To access the live webcast of the fireside chat, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available following the event. About Ardelyx, Inc.Ardelyx is a commercial-stage biopharmaceutical company focuse
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form SCHEDULE 13G filed by Ardelyx Inc.SCHEDULE 13G - ARDELYX, INC. (0001437402) (Subject)
- PRArdelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical MeetingsWALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation's (NKF) Spring Clinical Meetings, currently underway in New Orleans. XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialys
- SECSEC Form 10-Q filed by Ardelyx Inc.10-Q - ARDELYX, INC. (0001437402) (Filer)
- SECArdelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ARDELYX, INC. (0001437402) (Filer)
- PRArdelyx Reports First Quarter 2026 Financial Results and Provides Business UpdateQ1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million Strong financial position with $238.1 million in cash, cash equivalents and investments as of March 31, 2026 Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March
- SECSEC Form DEF 14A filed by Ardelyx Inc.DEF 14A - ARDELYX, INC. (0001437402) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)
- PRArdelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical MeetingsWALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract accepted for poster presentation, sharing data on the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and select nutrition biomarkers, at the National Kidney Foundation's (NKF) Spring Clinical Meetings, to be held May 7-10, 2026, in New Orleans. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chroni
- PRArdelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment patterns and their impact on gastrointestinal (GI) related healthcare resource utilization (HCRU), has been accepted as a poster presentation at the upcoming Digestive Disease Week Conference (DDW), to be held May 2-5, 2026, in Chicago. Information regarding DDW can be found here. Patient Factors Associated wi
- INSIDERSEC Form 3 filed by new insider Ettenberg Felecia3 - ARDELYX, INC. (0001437402) (Issuer)
ARDX FAQ
7 questionsWhat does Ardelyx Inc. do?
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of...Where does ARDX stock trade?
Ardelyx Inc. (ARDX) is listed on NASDAQ.What sector and industry is ARDX in?
Ardelyx Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ardelyx Inc. go public?
Ardelyx Inc. (ARDX) completed its IPO in 2014.What are analysts saying about ARDX?
Ardelyx Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight on 2026-01-09. Recent price targets range from $550.00 to $1400.00.What companies are similar to ARDX?
Notable peers in the same industry include KDNY (Chinook Therapeutics Inc.), AKBA (Akebia Therapeutics Inc.), ZSAN (Zosano Pharma Corporation). Compare ARDX side-by-side with any of them on Quantisnow.How can I track ARDX on Quantisnow?
Quantisnow aggregates Ardelyx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARDX to receive live email and push alerts on every new disclosure.